Regeneron Pharmaceuticals (REGN) Q4 2019 Earnings Call Transcript
REGN earnings call for the period ending December 31, 2019.
Regeneron Pharmaceuticals
REGN
REGN
$451.56
-$6.36
-1.4%
Price as of February 27, 2020, 1:03 p.m. EST
View Interactive REGN Charts
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Interactive Chart
News & Analysis: Regeneron Pharmaceuticals
The Fool has written over 400 articles on Regeneron Pharmaceuticals.
Regeneron Shares Rise on Earnings, Coronavirus Work
Two drugs drove its fourth-quarter sales growth, and the company expects to have an experimental treatment for 2019n-CoV coronavirus in a few months.
What's Behind Regeneron Pharmaceuticals' Great Q4 Results
Here's how the biotech topped Wall Street estimates on both the top and bottom lines in Q4.
FDA Agrees to Review Regeneron's Dupixent for Use by Younger Children
The eczema drug is already approved for patients 12 and older; this proposal would allow it to be prescribed to those as young as 6.
Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript
REGN earnings call for the period ending September 30, 2019.
Regeneron Pharmaceuticals Tops Q3 Estimates Thanks to Soaring Sales of 2 Drugs
As Eylea and Dupixent go, so goes Regeneron.
Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript
REGN earnings call for the period ending June 30, 2019.
Regeneron Pharmaceuticals Reports Marked Improvement in Q2
Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.
3 Top Biotech Stocks to Add to Your Watchlist
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
